SNWV

Company Overview — What Does SANUWAVE Health, Inc. Do?

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia. SANUWAVE Health, Inc. (SNWV) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. and employs approximately 40 people. With a market capitalization of $145M, SNWV is one of the notable companies in the Healthcare sector.

SANUWAVE Health, Inc. (SNWV) Stock Rating — Reduce (April 2026)

As of April 2026, SANUWAVE Health, Inc. receives a Reduce rating with a composite score of 40.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SNWV ranks #2,078 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, SANUWAVE Health, Inc. ranks #231 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SNWV Stock Price and 52-Week Range

SANUWAVE Health, Inc. (SNWV) currently trades at $16.84. The stock lost $1.32 (7.3%) in the most recent trading session. The 52-week high for SNWV is $46.59, which means the stock is currently trading -63.9% from its annual peak. The 52-week low is $20.84, putting the stock -19.2% above its annual trough. Recent trading volume was 86K shares, suggesting relatively thin trading activity.

Is SNWV Overvalued or Undervalued? — Valuation Analysis

SANUWAVE Health, Inc. (SNWV) carries a value factor score of 56/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 13.16x, compared to the Healthcare sector average of 23.63x — a discount of 44%. The price-to-book ratio stands at 87.85x, versus the sector average of 2.75x. The price-to-sales ratio is 3.55x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, SNWV trades at 7.04x EV/EBITDA, versus 6.34x for the sector.

Overall, SNWV's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

SANUWAVE Health, Inc. Profitability — ROE, Margins, and Quality Score

SANUWAVE Health, Inc. (SNWV) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is -1021.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -44.3% versus the sector average of -33.1%.

On a margin basis, SANUWAVE Health, Inc. reports gross margins of 77.5%, compared to 71.5% for the sector. The operating margin is 12.4% (sector: -66.1%). Net profit margin stands at -48.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 57.4% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

SNWV Debt, Balance Sheet, and Financial Health

SANUWAVE Health, Inc. has a debt-to-equity ratio of 1352.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.38x, suggesting adequate working capital coverage. Total debt on the balance sheet is $22M. Cash and equivalents stand at $10M.

SNWV has a beta of 0.69, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for SANUWAVE Health, Inc. is 44/100, reflecting average volatility within the normal range for its sector.

SANUWAVE Health, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, SANUWAVE Health, Inc. reported revenue of $40M and earnings per share (EPS) of $1.38. Net income for the quarter was $-17M. Gross margin was 77.5%. Operating income came in at $5M.

In FY 2025, SANUWAVE Health, Inc. reported revenue of $44M and earnings per share (EPS) of $1.38. Net income for the quarter was $12M. Gross margin was 77.1%. Revenue grew 35.0% year-over-year compared to FY 2024. Operating income came in at $5M.

In Q3 2025, SANUWAVE Health, Inc. reported revenue of $11M and earnings per share (EPS) of $1.13. Net income for the quarter was $10M. Gross margin was 77.6%. Revenue grew 20.4% year-over-year compared to Q3 2024. Operating income came in at $903,000.

In Q2 2025, SANUWAVE Health, Inc. reported revenue of $10M and earnings per share (EPS) of $0.06. Net income for the quarter was $551,000. Gross margin was 78.1%. Revenue grew 40.4% year-over-year compared to Q2 2024. Operating income came in at $1M.

Over the past 8 quarters, SANUWAVE Health, Inc. has demonstrated a growth trajectory, with revenue expanding from $7M to $40M. Investors analyzing SNWV stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SNWV Dividend Yield and Income Analysis

SANUWAVE Health, Inc. (SNWV) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SNWV Momentum and Technical Analysis Profile

SANUWAVE Health, Inc. (SNWV) has a momentum factor score of 16/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 65/100 reflects moderate short selling activity.

SNWV vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, SANUWAVE Health, Inc. (SNWV) ranks #231 out of 838 stocks based on the Blank Capital composite score. This places SNWV in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SNWV against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SNWV vs S&P 500 (SPY) comparison to assess how SANUWAVE Health, Inc. stacks up against the broader market across all factor dimensions.

SNWV Next Earnings Date

No upcoming earnings date has been announced for SANUWAVE Health, Inc. (SNWV) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SNWV? — Investment Thesis Summary

The quantitative profile for SANUWAVE Health, Inc. suggests caution. Momentum is weak at 16/100, a headwind for near-term performance.

In summary, SANUWAVE Health, Inc. (SNWV) earns a Reduce rating with a composite score of 40.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SNWV stock.

Related Resources for SNWV Investors

Explore more research and tools: SNWV vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SNWV head-to-head with peers: SNWV vs AZN, SNWV vs SLGL, SNWV vs VMD.